Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization.

Purpose: To compare two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization. Methods: A total of 61 eyes of 56 patients were treated: 26 eyes received a single injection followed by treatment pro re nata (1+ PRN), while 35 eyes first received 3 consecutive monthly injections (3+ PRN). Results: The mean follow-up was 53 +/- 16 months. The visual acuities were 51.9 +/- 16.2 letters with 3+ PRN and 53 +/- 22.4 letters with 1+ PRN at baseline (p = 0.824); 69.5 +/- 12.3 and 69 +/- 15.1 letters, respectively, at 12 months; and 67.1 +/- 16.2 and 66.4 +/- 19.7 letters, respectively, at the end of follow-up (p = 0.877). Mean survival until first retreatment after the loading dose was 36.9 +/- 6.1 months with 3+ PRN and 19.2 +/- 5.4 months with 1+ PRN (p < 0.001). Conclusions: Both dosing regimens led to similar visual outcomes. For eyes given a single injection in the first quarter, retreatment was needed appreciably earlier. (C) 2017 S. Karger AG, Basel